INTRODUCTION
============

The pancreas is a physiologically and biologically complex organ organized in exocrine and endocrine compartments which are modulated by a wide variety of neuronal and hormonal signals in an integrated manner. The exocrine function of the pancreas is performed by more than 90% of the whole pancreatic tissue and is essentially composed of acinar and ductal cells that respectively, synthesize and transport enzymes crucial for nutrient digestion at the gastrointestinal tract.

The endocrine function of the pancreas is in turn achieved by distinct cell types organized in major structures called Islet of Langerhans, which are scattered throughout the organ and are in close contact with the vascular environment. At least five major different endocrine cell types have been described: glucagon-secreting alpha-cells, insulin-secreting beta-cells, somatostatin (SST)-secreting delta-cells, ghrelin-producing epsilon-cells, and pancreatic polypeptide-producing cells. The distribution and proportion of endocrine cells within the pancreatic islets varies between species ([@B65]). The coordinated production, release, action, and relationship of the above-mentioned pancreatic endocrine peptides determine the constitutive metabolic homeostasis within the organism. In this sense, the endocrine dysfunction of the gland as the impairment of insulin production triggers the development of type 2 diabetes mellitus (T2DM) therefore, resulting in an abnormal regulation of blood glucose concentration with ulterior significant complications. It is widely known the close relationship between type 2 diabetes and obesity ([@B134]). In this sense, in fact, obesity is a multi-factorial chronic metabolic condition that predispose to the development of T2DM and shares with the later a common feature: insulin resistance ([@B110]). The increasing incidence of both metabolic disorders urges for the search of therapeutic targets in order to treat these pathologies and improve glucose homeostasis and insulin resistance, as well as body weight regulation. In this context, the action of the different ghrelin system components on glucose homeostasis, insulin resistance, and body weight regulation has been described and consequently, ghrelin system has been suggested as a potential drug target for the prevention or treatment of T2DM and obesity. In turn, some tissues are common targets of SST/cortistatin (CORT) and ghrelin (i.e., endocrine pancreas) and interestingly, these three molecules show a highly molecular parallelism (i.e., all peptides are processed from prepro-hormones that generate several biologically active peptides). In the present review, we analyze the literature relative to the modulation of endocrine pancreatic function by these two closely interrelated pleiotropic systems, SST/CORT, and ghrelin. Moreover, we also include its actions on glucose metabolism and insulin release as well as their possible pathophysiological role in metabolic disorders with increasing incidences as T2DM and obesity.

SST/CORT PLEIOTROPIC SYSTEM
===========================

Somatostatin was originally isolated from ovine hypothalamus based on its potent inhibitory action on pituitary growth hormone (GH) secretion ([@B14]). At circulation, it appears in two biologically active forms consisting of 14 (SST-14) or 28 amino acid (aa) residues (SST-28), generated by differential post-translational processing from a common precursor molecule. Both isoforms are widely distributed in a number of organs and tissues, although they display a particular tissue-specific expression patterns. Thus, SST-14 is predominantly produced in the central nervous system and in several peripheral tissues, including the pancreas ([@B6]), whereas SST-28 is mainly expressed by epithelial cells of the gastrointestinal tract mucosa. Such wide distribution of SST forms is consistent with its ever growing spectrum of biological and pathophysiological functions, mostly of inhibitory nature, such as inhibition of endocrine and exocrine secretions, neurotransmission, neuromodulation, gastrointestinal motility, immune system function, tumor cell growth, and pancreatic function ([@B96]).

A large amount of this wide biological capacity of SST is mediated via binding and activation of SST receptors, a family of five specific transmembrane proteins (named sst1--5) belonging to the superfamily of G proteins coupled receptors (GPCRs), and encoded by five distinct intronless genes ([@B40]). All five isoforms recruit several downstream transduction signals upon SST binding such as adenylyl cyclase and calcium channels, which are two major players involved in SST inhibitory action on hormone release. Similarly to SST tissue distribution, ssts are present in abundant tissue locations and often, in SST tissue targets, several isoforms are simultaneously present in the same cell. In this context, it has been reported that ssts functionally interact with each other and even with other GPCRs to form homo- and/or heterodimers that activate different signaling cascades and consequently mediate multiple biological actions ([@B90]).

The pleiotropic activity featured by SST fits well with both its ample tissue distribution and its multiple receptors. Moreover, it can also be likely related to the existence of a highly similar peptide of the same family, CORT, which was originally discovered in frogs and subsequently in rodents and humans ([@B31]; [@B124]). Like SST, CORT is the product of an enzymatically processed precursor, CORT prepro-peptide, which shares high homology with SST precursor. SST and CORT precursors are encoded by two different genes that evolved from a common ancestral gene by a duplication mechanism ([@B124]; [@B40]). Similar to that described for SST, processing of CORT precursor generates diverse mature peptides as CORT-14 and -29 in rodents and CORT-17 and -29 in humans. In addition, CORT- and SST-mature forms shares 11 aas, which include two cysteine residues responsible for their characteristic cyclic structure and the FWKT core (Phe7-Trp8-Lys9-Thr10), a crucial motif for receptor binding. Thus, their differences are located at the N- and C-terminal regions. In sum, CORT and SST sequence identity and structural homology explain well their close pharmacology, specifically, their comparable subnanomolar binding affinity to the five sst isoforms.

Although CORT was initially discovered in the brain and it is especially abundant in the cortex (where its name comes from), further reports showed that this neuropeptide is also widely distributed at peripheral tissues including gastrointestinal tract and pancreas. Based on its ability to activate ssts, CORT exhibits almost endocrine and most non-endocrine actions of SST ([@B19]; [@B41]). Actually, their main functional divergences, reside in the ability of CORT to promote sleep functions, modulate locomotor activity, exert potent anti-inflammatory actions in experimental models of inflammatory and autoimmune disorders ([@B31]; [@B47]) and, its influence on atherogenesis ([@B47]; [@B83]; [@B117]).

Differential actions between SST and CORT possibly reside in the ability of CORT to interact, in addition to ssts, with the Mas-related gene 2 receptor (MrgX2), a former orphan receptor originally suggested as specific for CORT. However, this receptor appears to be a quite promiscuous GPCR that also shows some specificity for proadrenomedullin and related peptides ([@B93]). Interestingly, CORT is also able to bind ghrelin receptor (GHS-R1a) by displacing its natural ligand from its binding sites, capacity that is not shared by SST. In this sense, it has been recently demonstrated that interaction of CORT with ghrelin system precludes CORT to be a mere SST natural analog in the regulation of endocrine secretions. Indeed, our laboratory have recently demonstrated that CORT exhibits a stimulatory role on prolactin (PRL) secretion in primates and mice, which could be blocked *in vitro* by a GHS-R1a antagonist, a biological action that is not elicited by SST ([@B27]).

GHRELIN PLEIOTROPIC SYSTEM
==========================

The ghrelin gene, *GHRL*, encloses a 20-bp non-translated exon (Ex0), four coding exons (Ex1--4) and three introns, being a 28-aa native ghrelin peptide the predominant product of the 117-aa precursor pre-proghrelin ([@B76]). Pre-proghrelin includes the signal peptide encoded by Ex1, and the coding sequence encoded by Ex2 and Ex3 which are the coding sequence of ghrelin ([@B114]). This transcript processing also generates different peptides or variants such as obestatin (of 23 aas), des-Glu14-ghrelin \[matching to native ghrelin except for the deletion of one aa (Glu in the position 14)\], etc. ([@B73]; [@B113]).

Native ghrelin was originally isolated from the stomach of humans and rats based on its potent GH releasing activity ([@B76]). Interestingly, native ghrelin has been the first natural hormone to be identified in which its third residue, usually a serine in mammals, contains the addition of a middle-chain fatty acid (*n*-octanoic acid) crucial for its biological activity. This post-translational modification is catalyzed by the ghrelin *O*-acyltransferase (GOAT; [@B57]; [@B143]), a membrane bound *O*-acyltransferase located at the endoplasmic reticulum that uses fatty acids from the diet to fulfill its action ([@B77]). Afterward, either acylated- or unacylated-proghrelin can be further processed by the prohormone convertase 1/3 (PC1/3) thus generating the acylated-ghrelin or its unacylated-ghrelin counterpart, a form of ghrelin initially considered as inactive ([@B145]). Surprisingly, circulating unacylated-ghrelin levels are significantly higher than those of acylated-ghrelin in a proportion that depends on the study considered ([@B61]; [@B144]; [@B18]; [@B82]).

Acylated-ghrelin elicits its biological actions through the GH-secretagogue receptor type-1a, GHS-R1a, previously known as an orphan receptor that mediates the GH-releasing effect of synthetic GH secretagogues, a group of peptide and non-peptide compounds with GH releasing properties. Currently, GHS-R1a is also called the ghrelin receptor based on the description of ghrelin as its natural ligand ([@B76]).

The GHS-R gene consist of two exons whose transcription and processing originate two distinct forms of cDNAs: GHS-R1a, encoded by both exons, and a shorter form, GHS-R1b, derived from the exclusive transcription of the first exon ([@B62]; [@B77]). The full-length of human GHS-R1a is a highly conserved protein of 366 aas that belong to the GPCR family containing seven putative membrane spanning alpha-helical segments and three intracellular and extracellular loops ([@B62]). GHS-R1a specifically recognizes the binding of acylated-ghrelin but not that of unacylated-ghrelin, whose specific receptor remains to be identified. In contrast, GHS-R1b isoform is an alternatively truncated variant of 289 aas that only possesses the first five transmembrane domains of GHS-1a ([@B62]; [@B77]), and it was considered, until recently, to be a non-functional GHS-R isoform based on its inability to bind acylated-ghrelin. Interestingly, it has been recently described the interaction of GHS-R1b with GHS-R1a and other receptors to form heterodimers ([@B92]), as well as the heterodimerization of GHS-R1a with SST and dopamine receptors ([@B113]).

In terms of signal transduction, it has been described that GHS-R1a activation involves the participation of several signaling cascades including phospholipase C (PLC), protein kinase C (PKC), protein kinase A ([@B77]) intracellular and extracellular Ca^2+^, and mitogen-activated protein kinases ([@B91]; [@B20]).

Different components of the ghrelin system have been found to be ubiquitously represented in the organism. Specifically, ghrelin was originally described to be predominantly produced by endocrine cells of the stomach submucosa ([@B76]). In addition, it was also documented to be produced at other portions of the gastrointestinal tract from the stomach to the colon and in a wide variety of peripheral tissues like the pancreas ([@B76]; [@B29]). It has also been showed the expression of ghrelin at different locations of the central nervous system ([@B128]). The wider ghrelin tissue distribution is mimicked by that of GOAT, particularly in major ghrelin-secreting tissues ([@B57]; [@B143]; [@B109]) although GOAT transcripts appear to be much lower expressed than ghrelin transcripts. However, it has been documented that a small proportion of ghrelin expressing cells devoid of GOAT expression thus suggesting and supporting that unacylated-ghrelin might show independent biological actions to that described for ghrelin ([@B68]) and most probably by distinct receptor and mechanisms to those recruited by ghrelin ([@B123]; [@B111]).

On the other hand, GHS-R1a expression has been also widely detected in tissues or organs including pancreas, liver, stomach, adipose tissue, small and large intestine, immune system, and others ([@B43]; [@B120]; [@B128]). In strikingly contrast, expression of GHS-R1b has been described to be even more extensive than that of GHS-R1a ([@B43]).

According to the wide tissue distribution of the different ghrelin system components, many physiological actions have been documented for this system. Based on the high conservation degree among species of ghrelin and its receptor sequences, it has been suggested that ghrelin system plays essential biological actions. In fact, and as mentioned earlier, acylated-ghrelin was initially identified based on its ability to stimulate GH release upon GHS-R1a coupling in a similar manner to that described for GH secretagogues ([@B76]). Also involving GHS-R1a activation, ghrelin elicits an orexigenic role by promoting food intake or appetite ([@B142]; [@B36], [@B35]) and weight gain and adiposity ([@B125]; [@B142], [@B141]). Ghrelin has also shown regulatory properties on glucose and energy homeostasis that will be revised separately. In addition to its metabolic actions, ghrelin has also been reported to exert potent anti-inflammatory actions in therapeutically relevant models of arthritis or inflammatory bowel disease ([@B46]; [@B47]) and also influence atherogenesis ([@B69]). Furthermore, ghrelin shows favorable effects on cardiovascular and gastroenteropancreatic physiology ([@B64]), as well as on the modulation of the immune system ([@B117]). At the central nervous system, ghrelin influences memory, learning, and behavior functions ([@B4]; [@B17]). Besides the above-described stimulatory effect on GH release, pituitary function is also regulates by ghrelin by stimulating the release of PRL and adrenocorticotropin ([@B131]; [@B25]).

On the other hand, unacylated-ghrelin, plays both equal or opposite biological actions to that above described for acyl-ghrelin, most probably through its coupling to a still unknown receptor different from GHS-R1a, as it has been recently suggested and documented ([@B123]; [@B80]; [@B121]). Moreover, regulation of unacylated-ghrelin secretion under food restriction condition has been reported, thus supporting a not passive role for this unmodified peptide ([@B75]).

Regarding obestatin, this 23-aa peptide is mainly produced in the stomach and at lower level in the pancreas, spleen, testis, duodenum, jejunum, colon, and mammary gland ([@B105]). To date, although obestatin receptor remains unknown, it has been proposed that GPR39 or glucagon-like peptide-1 receptor might be potential receptors for obestatin ([@B53]; [@B105]).

ACTIONS OF SST/CORT SYSTEM AT THE ENDOCRINE PANCREAS
====================================================

Somatostatin has long been known to potently modulate pancreatic function by playing a regulatory role on insulin and glucagon secretion. This tight regulation is accomplished by the coordinated action of SST biologically active forms. In this sense, SST-14 is the major product released by adult pancreatic delta-cells, whose contribution to total circulating SST accounts for nearly 5%. SST-14 immediate actions imply the paracrine regulation of other pancreatic endocrine cells. In addition, endocrine pancreatic function is also under the control of the major circulating SST form, SST-28. In this context, it has been documented that SST-14 and SST-28 differently target pancreatic alpha- or beta-cells. Accordingly, SST-14 has been associated with the inhibition of glucagon secretion while SST-28 seems preferentially to inhibit insulin secretion ([@B118]). In either case, inhibitory action of SST on both insulin and glucagon release would contribute to preserve glucose homeostasis which, in turn, retrospectively regulates SST plasma concentration. For this reason, during fasting, plasma SST level is low and increases up to twofold after meals. In such hyperglycemic conditions, insulin induces SST release and consequently shuts down its own release as a protective mechanism to prevent a rapid hypoglycemia at the post-prandial state. In contrast, SST release is also increased at low plasma glucose concentration as a consequence of the coordinated action of glucagon and L-glutamate, a co-secretion product of alpha-cells ([@B118]).

The SST action on pancreatic hormones is mediated by its interaction with the different receptor isoforms, however, conflicting data about receptor expression at the pancreatic level have been published which, might be related with the different method used and/or species analyzed. In general, it is likely that endocrine pancreas expresses all five sst isoforms, being probably sst1, sst2, and sst5 those expressed in a predominant manner. Specifically, it has been demonstrated by RT-PCR that rodent pancreas expresses all sst isoforms except sst4. In turn, by double immunohistochemistry methods, it has been confirmed the expression of sst2 and sst5 in both rodent beta- and delta-cells. In humans, it has been reported a predominant expression of sst2 in alpha-cells, sst1 and sst5 in beta-cells, and sst5 in delta-cells while there is not consistent data on the expression of the rest of ssts ([@B118]; [@B40]).

In addition, and in order to ascertain the subtype receptors underlying the inhibitory effect of SST on pancreatic hormones, specific receptor agonists, and antagonists as well as *knock out* mouse models with deletion of the different ssts isoforms have been employed. These issues have been amply revised elsewhere ([@B118]) and briefly, it appears that sst2 seems to mediate glucagon inhibition and sst5 looks as the main receptor mediating insulin inhibition in rodents. More recently, high expression of sst3 has been also demonstrated in mouse pancreatic islets ([@B103]). In human, by contrast, sst2 looks to be the main receptor mediating both insulin and glucagon release, although sst1 and sst5 also participate in the regulation of insulin secretion ([@B40]). In summary, several sst isoforms would mediate the inhibitory action of SST on insulin and glucagon secretion through a mechanism that indubitably is species-dependent, and will essentially depend on the receptor expression pattern.

In relation to CORT and its role on pancreatic function, only a few studies are available. Particularly and similarly to SST, CORT expression has been reported at the endocrine pancreas and essentially mimics its inhibitory action on insulin secretion under physiological and certain pathological conditions ([@B55]; [@B19]), although the molecular mechanism underlying such inhibitory action is still unclear. In addition, it should be highlighted that CORT is also able to elicit distinct functions to that showed by SST mainly through its coupling to the ghrelin receptor (GHS-R1), as it has been recently documented for others endocrine secretions ([@B27]).

ACTIONS OF GHRELIN SYSTEM AT THE ENDOCRINE PANCREAS
===================================================

After ghrelin discovery, it was reported that pancreatic epsilon-cells are the major source of ghrelin forms during fetal life until early post-natal period ([@B138]; [@B22]). After this period, the major source of ghrelin production is the stomach submucosa ([@B76]) while, the pancreas turns on a secondary source of ghrelin production with low level of ghrelin receptor expression ([@B133]). At the pancreas, the major source of ghrelin resides into epsilon-cells ([@B138], [@B139]; [@B99]) although it appears that is also produced by beta-cells in humans ([@B137]) and by glucagon-producing alpha-cells in human and rats ([@B30]). In any case and in terms of ghrelin production, it has been described that during adult life the 65--90% of circulating ghrelin corresponds to that synthesized and released by the stomach, being the rest derived from other tissues including the pancreas and the intestine ([@B1]).

Endocrine ghrelin actions at the pancreas involve inhibition of SST release by delta-cells, and stimulation of glucagon release by alpha-cells ([@B101], [@B100]; [@B133]; [@B23]) as well as inhibition of pancreatic polypeptide release by PP cells ([@B100]; [@B79]), being all cells types in which GHS-R expression has been documented ([@B138], [@B139]; [@B70]; [@B34]; [@B48]). On the other hand, SST and glucagon have also been shown to elicit a reciprocal modulation of ghrelin production (**Figure [2](#F2){ref-type="fig"}**). Furthermore, it has been reported that insulin and SST inhibit ghrelin release while glucagon inhibits its secretion in rodent although stimulate ghrelin release in humans ([@B100]).

Although ghrelin effect on insulin secretion is supported by an increasing number of reports, its precise role is nevertheless controversial since either stimulatory or inhibitory actions has been reported depending on the ghrelin doses used and/or experimental conditions employed as recently reviewed by [@B48], [@B49]. Specifically, the ghrelin stimulatory effect of insulin release is mainly mediated by an increase of cytosolic Ca^2+^ upon GHS-R activation, while the participation of a different receptor has been proposed based on the observed stimulatory action of both acylated- and unacylated-ghrelin on insulin release in a hamster beta-cell line devoid of GHS-R expression ([@B52]). In addition, it has also been described that ghrelin administration increases insulin release in rats under conditions of low blood insulin as a consequence of a 90% pancreatectomy ([@B71]). Reciprocally, insulin inhibits ghrelin expression ([@B133]) and more recently it has been proposed that insulin might act as an inhibitor of pancreatic ghrelin activation by inhibition of GOAT expression ([@B2]).

In clear contrast to the above stimulatory role of ghrelin on insulin secretion, the ghrelin inhibitory action has been prevalently reported and examined in several biological and animal models including cultured pancreata, cultured islets and heterologous cell models ([@B48]; [@B32]), as well as by using several methodological approaches. Overall, it has been described that ghrelin administration significantly reduces insulin secretion ([@B16]; [@B122]), and this action was blocked in the presence of a higher dose of unacylated-ghrelin, suggesting the participation of a receptor distinct to GHS-R on insulin secretion modulation ([@B100]). Reduction of insulin level by ghrelin administration triggers a concomitant elevation of blood glucose levels in a dose-dependent manner as well as deterioration of insulin sensitivity during glucose tolerance, as it have been described in both humans and rodents ([@B78]; [@B34]; [@B122]; [@B111]). The hyperglycemic action of ghrelin, but not by unacylated-ghrelin in rodents, was blocked by simultaneous administration of GHS-R antagonist thus revealing the specific participation of GHS-R in the hyperglycemic role of ghrelin ([@B34]). In addition, GHS-R deletion also reduces blood glucose level and significantly enhances insulin sensitivity ([@B84]; [@B102]). Importantly, the involvement of GH (a long time known hyperglycemic hormone) has been excluded from the hyperglycemic effect of ghrelin administration based on elevated plasma glucose levels observed in response to exogenous ghrelin administration in GH-deficient mice ([@B34]) and subjects with GH-deficiency ([@B136]). Similarly, ghrelin hyperglycemic effect have been reported to be independent of an insulin resistance induction as evidenced by insulin and glucose tolerance tests after ghrelin administration ([@B34]).

In order to ascertain whether the insulinostatic action of ghrelin is due to the peptide derived from the stomach or other sources as the pancreas, GHS-R antagonist was administered to gastrectomized animals and a significant increase in insulin secretion was observed in a similar extend to that observed in normal rats. This observation suggests that intra-islet ghrelin may locally act on insulin production regulation ([@B33]). However, [@B7] recently reported that intra-islet ghrelin does not play a major local role on the regulation of insulin release *in vivo*, based on their findings on transgenic mice in which ghrelin and GOAT were overexpressed in beta-cells. The discrepancy between these two later studies may reside on the different ghrelin concentration reached at the surrounding microenvironment of beta-cells.

In addition to the regulatory role of ghrelin on pancreatic function, it has also been described that acylated- and unacylated-ghrelin as well as obestatin elicit a protective role by preventing apoptosis on pancreatic islet in rodents, humans, and several beta-cell lines ([@B51]). In this sense, it has been reported that beta-cell destruction elicited by streptozotocin administration was precluded by ghrelin by increasing both beta-cell mass and insulin release in rats ([@B63]). Furthermore, ghrelin and obestatin also protect against apoptosis induced by serum starvation and cytokines in both human islets and beta-cell lines ([@B52], [@B53], [@B48]). In well agreement with this, ghrelin and obestatin exert their mitogenic effect by increasing the number of beta-cells in 90% pancreatectomized rats ([@B71]) and in a hamster beta-cells line ([@B48]), proliferative action that was blocked by administration of ghrelin antagonist or ghrelin antibody ([@B71]; [@B48]). These findings suggest that a cross-talk between ghrelin and obestatin may exist ([@B53]).

ROLE OF SST/CORT SYSTEM IN T2DM AND OBESITY
===========================================

%They are not many reports on the role of SST/CORT in situations with altered metabolic conditions. In this sense, an increase in the number of SST-producing cells in T2DM patients has been recently described, although circulating SST remains in the same level to that depicted by control subjects. However, in an experimental model of obese and spontaneously diabetic mice, SST content is significantly increased ([@B118]). In this scenario, the well established inhibitory actions of SST on pancreatic function, particularly on insulin and glucagon secretion (**Figure [1](#F1){ref-type="fig"}**) as well as its inhibitory action on intestinal glucose absorption, predicted its use as a key tool to potentially regulate glucose homeostasis and insulin sensitivity in diabetes and obesity ([@B58]; [@B127]). Indeed, initial studies evaluated SST role on insulin hypersecretion as well as in hyperinsulinemia associated with obesity, two conditions that were described to induce insulin resistance ([@B66]; [@B11]). Consequently, significant reductions in body weight and insulin release as well as an improvement of insulin sensitivity were observed in obese patients treated with synthetic SST analogs ([@B12]; [@B132]; [@B85]; [@B127]), which were originally developed as a consequence of the SST short half-life. Similarly to SST, it has also been reported an inhibitory action of CORT on insulin release in patients with acromegaly or prolactinoma ([@B54]). In relation to CORT, and based on its described anti-inflammatory properties, it would be of interest to explore its role on the inflammatory signaling that occurs during obesity conditions.

![**Diagram of SST actions on islet cell release.** Arrow heads represent SST from extrapancreatic origins (mostly intestinal).](fendo-03-00114-g001){#F1}

![**Diagram of ghrelin actions on islet cell release.** Arrow heads represent ghrelin from extrapancreatic origins (mostly stomach). "\>\>\>" denotes that the majority of published studies describe an inhibitory effect of ghrelin on insulin release.](fendo-03-00114-g002){#F2}

More recently, the effect of a multi-ligand SST analog (pasireotide) on hormones that mediate glucose homeostasis has been described in healthy volunteers ([@B44]; [@B115]). Accordingly, based on the high binding affinity for four of the five SST receptor subtypes (sst1--3, and sst5) elicited by pasireotide, it has been administered to healthy subjects and an elevation of blood glucose has been observed mainly as a consequence of its inhibitory action on both insulin and glucagon release ([@B115]). Similar hyperglycemic effect of pasireotide has been observed in clinical trials in which pasireotide administration was evaluated on patients with endocrine pathologies as Cushing's disease, acromegaly, and neuroendocrine tumors (NETs). In these pathologies, hyperglycemia might be further worsened in base to their inherent hormonal nature ([@B13]; [@B97]; [@B26]). Furthermore, variable sst1--5 expression has been extensively documented and consequently SST analogs have been classically used after adenoma or tumor resection. Lastly, SST analogs have been used as a first option therapy in selected patients upon its ability to reduce hormonal release and/or to inhibit tumor mass progression. In these cases, alterations in glucose homeostasis as well as impaired insulin resistance has been well documented as a secondary effect to their characteristic underlying hormonal secretion ([@B106]; [@B115]).

In different series of acromegalic patients, a significant prevalence of impaired glucose metabolism and diabetes mellitus has been described, a consequence that is believed to be originated by the excess GH ([@B130]; [@B38]; [@B39]; [@B74]). In such GH hypersecreting conditions, the universal sst binding profile of pasireotide and its higher efficacy by lowering GH release more significantly than sst2 preferential or specific SST analogs (octreotide and lanreotide) granted its therapeutical use. However, as mentioned above in these subjects, the risk of hyperglycemia increases as a common adverse event originated by the normalization of GH and IGF-1 levels as well as the inhibition of insulin release by SST administration ([@B106]).

Somatostatin analogs have also been applied in the management of NET suffering patients in which, similarly to acromegalic individuals, an altered glucose tolerance has been documented ([@B24]). Such altered glucose tolerance may occur as a consequence of hormonal dysregulation or pancreatic resection ([@B106]; [@B67]).

Hypercortisolism condition, a distinctive characteristic of Cushing's disease, also leads to hyperglycemia and reduced glucose tolerance and as a result, in an increase of the prevalence of diabetes in this pathology ([@B87], [@B88]; [@B106]). Furthermore, hyperglycemia persists even when cortisol level declines by administration of SST analogs, i.e., pasireotide as it has been recently reported ([@B26]).

In sum, hyperglycemia conditions occur in an elevated proportion of individuals suffering of acromegaly, Cushing's disease or NET and accordingly, it has been proposed that regular blood glucose testing and insulin analogs will be required, particularly when SST analogs are therapeutically used in these pathologies ([@B106]; [@B26]).

ROLE OF GHRELIN SYSTEM IN T2DM AND OBESITY
==========================================

As mentioned earlier, a growing body of studies supports the inhibitory role of ghrelin on insulin release *in vivo* and *in vitro* and its influence on glucose tolerance. Accordingly, it has been proposed that the antagonism of ghrelin system components could improve glucose homeostasis and/or beta-cell function under certain metabolic disorders as T2DM, a complex disease with a strong genetic, behavioral, and environmental background that is characterized by two distinctively conditions: insulin resistance and progressive beta-cell dysfunction. In T2DM, beta-cells become unable to adequately increase insulin release to compensate insulin resistance and consequently leading to a situation of hyperglycemia. It is well known the close association between T2DM and obesity in terms of metabolic imbalance and their common features, insulin resistance, in which ghrelin system could be of relevance based on its ability to modulate both glucose homeostasis and weight loss ([@B37]).

Under normal metabolic conditions, circulating ghrelin and plasma glucose concentrations are inversely related. In fact, ghrelin levels are increased under fasting conditions or immediately before meals and significantly decreased after feeding ([@B3]). Obviously, the meal-related pattern of ghrelin is also opposite to that depicted by insulin and consequently the fall of ghrelin at post-prandial state has been argued to partially depend on the rise of insulin release after food intake ([@B116]). Accordingly, the tight relationship between ghrelin and insulin also relies in the general assumption that insulin elicits a negative action on both plasma acylated- and unacylated-ghrelin concentration ([@B107]; [@B89]), while administration of acylated-ghrelin results in insulin resistance ([@B42]).

In subjects affected by T2DM and consequently resistant to insulin, it has been showed that blood ghrelin concentration was chronically lower than that observed in healthy subjects even when age, sex, and body mass index (BMI) were adjusted, probably as a direct effect of insulin on ghrelin-producing cells ([@B98]; [@B3]; [@B135]). Based on the influence of ghrelin on insulin release and glucose homeostasis, it has been suggested that ghrelin antagonism could be of interest to treat T2DM and related metabolic pathologies. In this context, it has been shown that deletion of ghrelin gene promotes insulin release and ameliorates glucose intolerance and hyperglycemia in a diabetic and obese mice model ([@B119]). In well agreement with this, GHS-R ablation also improves insulin sensitivity ([@B45]). Likewise, it has also been documented an improvement of glucose homeostasis in streptozotocin-induced diabetic rats treated with obestatin ([@B49]) as well as a reduction in insulin resistance in mice fed with a high fat diet ([@B50]).

On the other hand, obesity conditions have been associated with some ghrelin and GHS-R gene variations although some discrepancies exist depending on studies and population considered ([@B94]; [@B81]; [@B129]). In this sense, available data are still inconclusive and might be limited by some relatively small analyzed cohorts that might restrict the power of association.

However, it has been well documented that under obesity conditions plasma ghrelin levels negatively correlate with BMI and consequently with factors or parameters that are elevated in obesity such as insulin, leptin, and fat mass ([@B126]). In this sense a chronic lower ghrelin plasma concentration in obese children and adults has been reported in comparison with those of age-matched lean controls ([@B126]; [@B104]; [@B112]). Similar data have been cited for Pima Indians, a population reported with the highest prevalence rates of obesity and T2DM when compared with Caucasians ([@B126]). Similarly to that reported under normal metabolic condition, ghrelin also elicits a meal-related pattern although under obesity conditions the fall of ghrelin level at post-prandial state is less pronounced. Such downregulation might be a consequence of elevated fasting insulin or leptin levels observed in obesity ([@B8]). In this sense, it has also been suggested that the decreased secretion of ghrelin, could be responsible for the concomitant decreased levels of circulating GH observed in obese individuals ([@B86]; [@B126]). More recently, the decreased ghrelin concentration observed in obesity could be an adaptive mechanism to maintain energy homeostasis has also been proposed ([@B126]). In rodents, diminished ghrelin levels have been found at tissue level as well as a significant reduction in plasma ghrelin concentration and synthesis in obesity conditions induced by diet ([@B108]; [@B5]).

Targeting ghrelin system components by different pharmacological, immunological, and genetic approaches have been addressed in order to promote weight loss and to improve obesity conditions (i.e., insulin resistance). Thus, some studies evaluated pharmacological approaches to block or neutralize either ghrelin or its receptor under diet-induced obesity and how these methods ameliorate obesity condition by reducing appetite or food intake, and ultimately inducing weight loss ([@B140]; [@B112]; [@B15]). Another set of studies, examined the protection of ghrelin system against rapid weight gain by exposure to a high fat diet by knocking out either ghrelin ([@B140]) or GHS-R ([@B21]). In these studies, an improvement of glucose tolerance was observed even though there is no effect on body weight ([@B146]; [@B84]). Similar data were obtained in a genetically obese mice model (ob/ob; leptin deficient) in which the improvement of insulin sensitivity and glucose homeostasis was attributed to ghrelin although the obese phenotype remains unchanged ([@B119]).

In addition, it has also been proposed that GOAT by a specific inhibitor could be a potential treatment against obesity by inhibiting ghrelin acylation and consequently avoid weight gain ([@B56]; [@B143]; [@B45]; [@B9]).

On the other hand, diet-induced weight loss elicits an increase in circulating ghrelin levels thus normalizing them until near optimal concentration, rise that probably may hamper the sustained weight loss ([@B28]; [@B59]). In cases of morbid obesity, a more drastic method as bariatric surgery has been employed in order to reduce metabolic complications associated to obesity. Interestingly and contrary to that reported in diet-induced weight loss, after bariatric surgery ghrelin level significantly decreases and insulin sensitivity is rapidly restored, thus improving the associated diabetic state ([@B10]; [@B60]). In this context, sustained low ghrelin level reached by this surgical procedure precludes or delays weight gain by reducing hunger, an effect that is not observed in procedures as weight loss by diet modification in which ghrelin levels gradually normalizes with a consequent weight gain. On the other hand, in morbid obese patients, it has been suggested that equimolar administration of acylated- and unacylated-ghrelin also improve insulin sensitivity ([@B72]).

Unfortunately, there is not yet a ghrelin system based therapy that ensures a sustained weight loss, although ghrelin antagonist and/or GOAT inhibitors may be considerate good therapeutic candidates for the treatment of T2DM and obesity.

CONCLUSION
==========

The complex relationship of ligand--receptor architecture of SST/CORT and ghrelin systems is complemented by the functional relevance of their common tissue targets. Indeed, besides their opposite influence on GH release at the pituitary level, SST/CORT and ghrelin systems act on the same cellular target to influence common and relevant biological actions as it is the case of their interactions on beta cell function and survival as well as on glucose homeostasis and insulin resistance. However, the underlying molecular mechanisms of these actions have not been fully elucidated yet. Interestingly, different and severe metabolic dysfunctions as T2DM and obesity have been described to modulate their circulating levels and the expression of some components of both systems at hypothalamic, pituitary, or pancreatic level. In sum, there are an increasing number of evidences that support a potential contribution of SST/CORT and ghrelin system components in the endocrine pancreas dysfunction in prevalent neuroendocrine-metabolic pathologies (T2DM and obesity) which suggest that these systems could be considered as future valuable therapeutic targets for the prevention or treatment of such metabolic disorders. In this sense, future research will be of particular importance in order to ascertain whether SST/CORT and ghrelin systems and its receptors will act at pancreatic islets under physiological and pathological conditions. Likewise, the underlying molecular mechanisms as well as the precise role and the contribution of islet derived-SST, -CORT, and -ghrelin in the pancreatic endocrine deregulation and/or the resulting insulin resistance under severe metabolic conditions should be investigated.
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